MK-3328 is azabenzoxazole derivative patented by American multinational pharmaceutical company Merck & Co., Inc. as amyloid binding compound useful for diagnostic evaluation changes of amyloid plaque level in living patients with Alzheimer’s disease. In preclinical trials MK-3328 was identified as a promising candidate, exhibiting amyloid binding potency balanced with low levels of nonspecific binding. In vivo,[18F]MK-3328 demonstrates favorable kinetics, exhibiting high brain uptake and good washout in normal rhesus monkey PET imaging studies. In 2011 MK-3328 was studied in phase I clinical trials but no further development reports were published.